Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours
Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Journal
Book Volume: 22
Journal Issue: 8
DOI: 10.1007/s11864-021-00863-y
Abstract
Opinion statement Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with rising incidence and prevalence. Outcome and therapy of small bowel neuroendocrine tumours (SBNETs) is variable, depending on the grade, differentiation, tumour burden, as well as the site of the tumour origin. Because of this, multidisciplinary approach is essential. Large randomized clinical trials, with somatostatin analogues (PROMID, CLARINET) or with peptide receptor radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial) as well as the mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials), represent milestones for the medical management of unresectable grade 1 and 2 SBNETS over the last decade. Novel therapies, such as tyrosine kinase inhibitors (TKI), are on the cutting edge. However, multiple unsolved questions remain. This review provides a comprehensive review of the main systemic therapeutic options for advanced SBNETs and discusses the latest guideline recommendations for palliative treatment.
Involved external institutions
Christie NHS Foundation Trust
United Kingdom (GB)
Uppsala University Hospital / Akademiska sjukhuset
Sweden (SE)
University of Manchester
United Kingdom (GB)
University of Bari Aldo Moro / Università degli Studi di Bari Aldo Moro
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Ramón y Cajal
Spain (ES)
United Kingdom (GB)
Uppsala University Hospital / Akademiska sjukhuset
Sweden (SE)
University of Manchester
United Kingdom (GB)
University of Bari Aldo Moro / Università degli Studi di Bari Aldo Moro
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Italy (IT)
Hospital Universitario Ramón y Cajal
Spain (ES)
How to cite
APA:
Dawod, M., Gordoa, T.A., Cives, M., De Mestier, L., Crona, J., Spada, F.,... Lamarca, A. (2021). Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Current Treatment Options in Oncology, 22(8). https://dx.doi.org/10.1007/s11864-021-00863-y
MLA:
Dawod, Mohammed, et al. "Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours." Current Treatment Options in Oncology 22.8 (2021).
BibTeX: Download